IL6 Inhibitors in RA

A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study

Currently, although several categories of biological disease-modifying antirheumatic drugs (bDMARDs) are available, there are few data informing selection of initial treatment for individual patients with rheumatoid arthritis (RA). Therefore, tumor necrosis factor inhibitor (TNF-i) and tocilizumab (...

RA outcomes better with tocilizumab than TNFi as first biologic therapy

Patients with rheumatoid arthritis who initiate tocilizumab as their first biologic therapy after failure…

IL-6 Inhibitor Kevzara Granted FDA Approval for Rheumatoid Arthritis

The FDA has approved sarilumab (Kevzara), a new IL-6 inhibitor co-developed by Regeneron and Sanofi's, for use in adults with moderate to severe rheumatoid arthritis (RA).

Janssen Presents Long Term Phase 3 Efficacy and Safety Data of Sirukumab in Rheumatoid Arthritis Patients Who had an Inadequate Response and/or Who Were Intolerant to Anti-TNFs

MADRID , June 14, 2017 /PRNewswire/ -- Sirukumab Phase 3 Data Presented at the Annual European Congress of Rheumatology (EULAR ) 2017 a lso Show Significant Improve ment in Quality of Life Measures Janssen-Cilag ...

J&J arthritis drug sirukumab raises safety concerns: FDA staff

Image result for fda disapproved

There were more deaths in patients taking Johnson &…

No Comments Yet.

Leave a comment